EHDI 1-3-6 pathway: screen, diagnose, and intervene before the critical language window closes
Since universal newborn hearing screening (UNHS) became standard of care in the United States in the early 2000s, more than 98% of newborns are screened before hospital discharge. Two physiologic technologies make this possible: otoacoustic emissions (OAE), which test the cochlea, and automated auditory brainstem response (AABR), which tests the entire auditory pathway from ear to brainstem.
A healthy cochlea does not just receive sound — its outer hair cells actively amplify incoming vibrations, and in doing so they generate a faint sound of their own that travels back out through the middle ear into the ear canal. This is an otoacoustic emission. A soft foam probe placed in the infant's ear canal delivers a series of clicks or tone bursts (transient-evoked OAE, TEOAE) or two simultaneous tones (distortion-product OAE, DPOAE), and a sensitive microphone in the same probe listens for the resulting echo.
If outer hair cells are functioning normally, an echo of measurable amplitude returns within milliseconds. If the cochlea is damaged — or if the middle ear is blocked by residual amniotic fluid or vernix, a common cause of false "refers" in the first 24-48 hours — no measurable echo is detected and the infant receives a "refer" result requiring rescreening or diagnostic follow-up.
OAE is fast (under 5 minutes per ear), inexpensive, and requires no electrodes, making it the default first-tier screen in most well-baby nurseries.
AABR presents clicks through a small earphone while three surface electrodes placed on the forehead and mastoids record the tiny electrical response generated as the sound signal travels along the auditory nerve and through the brainstem. A built-in algorithm statistically compares the recorded waveform to a normative template and returns an automated "pass" or "refer" — no audiologist interpretation is required at the screening stage.
Critically, AABR tests the entire pathway — cochlea, auditory nerve, and brainstem — whereas OAE tests only the cochlea. This distinction matters most in the neonatal intensive care unit (NICU): infants with auditory neuropathy spectrum disorder (ANSD) have normal outer hair cell function (a passing OAE) but abnormal or absent neural transmission, so a passing OAE alone would miss the diagnosis. For this reason, the Joint Committee on Infant Hearing (JCIH) recommends AABR as the required screening modality for any infant with more than 5 days in the NICU.
OAE alone can miss auditory neuropathy spectrum disorder because it only interrogates cochlear outer hair cells, not the neural pathway. NICU graduates — who carry the highest risk for ANSD from hyperbilirubinemia, hypoxia, and ototoxic medication exposure — must be screened with AABR, not OAE alone.
A refer result on the newborn screen is common and, most of the time, does not indicate permanent hearing loss. Transient causes of a false-positive refer include residual middle-ear fluid or vernix caseosa in the ear canal, background noise in a busy nursery, probe misplacement, and the test being performed too soon after birth (before the ear canal fully clears).
Because of this, the standard two-step protocol calls for a rescreen (ideally on both ears, using AABR if the initial screen was OAE-only) before an infant is referred onward to full diagnostic evaluation. Even so, the emotional impact on families of a refer result is significant, and clear risk communication at this stage is one of the strongest predictors of whether a family returns for follow-up.
| Product | Indication | Trial Design | Key Result |
|---|---|---|---|
| OAE (TEOAE / DPOAE) | Outer hair cell (cochlear) function only | Click/tone stimulus; microphone records cochlear echo in ear canal | Fast, cheap, no electrodes — standard for well-baby nursery |
| AABR | Cochlea + auditory nerve + brainstem pathway | Click stimulus; scalp electrodes record evoked neural waveform vs. normative template | Detects auditory neuropathy — required for NICU >5 days |
| Two-step OAE→AABR protocol | Well-baby population, cost-optimized | OAE first pass/refer; AABR used to rescreen OAE-refers before diagnostic referral | Reduces false-positive referrals while preserving sensitivity |
| Combined OAE + AABR (NICU) | High-risk NICU graduates | Both modalities performed to separately assess cochlear and neural function | Captures ANSD that OAE-only protocols would miss |
The newborn hearing screen is only the first link in a chain — and it is the weakest link that determines outcomes. Every infant with a refer result must be tracked to a diagnostic evaluation, but families face a cascade of barriers between hospital discharge and that appointment, and a large share of referred infants simply disappear from the system.
The EHDI system distinguishes two related failures. "Loss to follow-up" (LTF) means a referred infant never completed the recommended diagnostic evaluation. "Loss to documentation" (LTD) means the evaluation may have happened, but the result was never reported back to the state EHDI tracking program — so from a public-health surveillance standpoint, the infant is invisible either way.
Combined, LTF/D affects roughly one in three infants who refer on newborn screening nationally, though state programs range from under 10% to over 50% depending on tracking infrastructure, care coordination staffing, and access to pediatric audiology services.
Loss to follow-up is rarely a single failure — it is usually the accumulation of several barriers:
• Family-level: low health literacy about what a "refer" result means, lack of transportation, competing medical or social needs, language barriers, and the false reassurance that "the baby responds to sound at home" • System-level: shortage of pediatric audiologists (many rural counties have none within driving distance), long wait times for the diagnostic ABR appointment, and insurance authorization delays • Communication-level: inconsistent messaging from screening staff, discharge paperwork that undersells the urgency, and no structured hand-off between birthing hospital, primary care pediatrician, and audiology
Infants born in rural areas, to non-English-speaking families, and without private insurance are disproportionately represented among those lost to follow-up — turning a preventable systems failure into a health equity issue.
Every month of delay in the 1-3-6 pathway is not neutral — it is a month subtracted from the period of maximum auditory neuroplasticity. A refer result that "resolves itself" by disappearing from the system can silently convert a treatable case into a permanent developmental deficit.
Programs that succeed in reducing loss to follow-up share common features: a dedicated care coordinator or "navigator" who personally contacts every refer family within days of discharge; scheduling the diagnostic ABR appointment before the family leaves the hospital rather than asking them to self-schedule; automated electronic health record flags that alert the pediatrician at the first well-child visit; and telehealth or mobile diagnostic units for families in audiology deserts.
Some state EHDI programs have cut LTF/D rates from over 40% to under 10% within a few years using exactly these interventions — proof that the "6-month cliff" is a solvable logistics problem, not an inevitability.
Unlike the automated pass/refer screen performed at birth, the diagnostic ABR is a threshold-seeking test interpreted by a pediatric audiologist. Sound intensity is varied systematically to find the softest level at which a reliable neural response appears — producing an ear-specific, frequency-specific estimate of hearing sensitivity that can confirm or rule out permanent hearing loss.
When a click stimulus is delivered, the resulting neural volley produces a predictable sequence of five to seven voltage peaks over the first ~8 milliseconds, each generated by a different way-station along the auditory pathway:
• Wave I — the distal auditory nerve, near the cochlea • Wave II — the proximal auditory nerve, at the brainstem entry • Wave III — the cochlear nucleus • Wave IV — the superior olivary complex • Wave V — the lateral lemniscus / inferior colliculus, the most robust and clinically important peak
Because the response is thousands of times smaller than background brain electrical activity, the audiologist presents the stimulus hundreds to thousands of times and computer-averages the recordings — random EEG noise cancels out while the time-locked evoked response reinforces, revealing the waveform.
The audiologist begins at a comfortable, clearly audible intensity (e.g., 80–90 dB nHL) and progressively lowers the stimulus level, tracking Wave V as it becomes smaller and shifts to a later latency, until the wave can no longer be reliably identified. The lowest intensity producing a repeatable Wave V is the estimated threshold for that frequency and ear.
This is repeated using frequency-specific tone-burst stimuli (typically 500, 1000, 2000, and 4000 Hz) rather than broadband clicks alone, because click-ABR threshold predominantly reflects the 2000–4000 Hz region and can miss losses isolated to low or high frequencies. Bone-conduction ABR (stimulus delivered via a vibrator on the mastoid, bypassing the outer and middle ear) is added whenever air-conduction thresholds are elevated, to distinguish a conductive component (outer/middle ear) from a sensorineural component (cochlea/nerve).
A prolonged Wave I-to-V interpeak latency with a present Wave I suggests a neural/retrocochlear problem, while an absent or grossly abnormal ABR despite present OAEs is the hallmark of auditory neuropathy spectrum disorder — a distinction that changes the entire intervention plan.
The 3-month diagnostic benchmark balances two competing needs: giving the family time to navigate scheduling and giving the auditory and language system as much intervention time as possible before the neuroplastic window narrows. In practice, many centers can complete diagnostic ABR by 6-8 weeks of age when referral is prompt, well before the 3-month ceiling — every week gained here is a week added to the intervention runway.
A full audiologic diagnostic evaluation also includes tympanometry (middle-ear pressure/mobility), acoustic reflexes, and case history/genetic risk-factor review, not ABR alone — together these determine whether the loss is conductive, sensorineural, or mixed, unilateral or bilateral, and stable or potentially progressive (as with connexin 26 mutations or congenital CMV).
Once diagnostic testing is complete, thresholds are plotted on an audiogram — the standard graphical language of hearing, with frequency (pitch, in Hz) on the horizontal axis and intensity (loudness, in dB HL) on the vertical axis. This single chart determines severity classification, likely etiology clues, and the shape of the intervention plan.
Hearing threshold is graded in decibels Hearing Level (dB HL), calibrated so that 0 dB HL represents the average softest sound a normal-hearing young adult can detect at each frequency. Standard severity categories are: Normal (≤15 dB HL), Slight (16-25), Mild (26-40), Moderate (41-55), Moderately Severe (56-70), Severe (71-90), and Profound (>90 dB HL).
Beyond overall severity, the configuration matters clinically: a downward-sloping audiogram (worse at high frequencies) is common in genetic and noise-related loss and disproportionately affects consonant perception (critical for speech clarity), while a flat loss affects all frequencies roughly equally, and a low-frequency loss (rarer) can spare speech understanding more than its severity would suggest.
Comparing air-conduction thresholds (sound through the ear canal and middle ear) with bone-conduction thresholds (sound delivered directly to the cochlea, bypassing the outer/middle ear) reveals the type of loss:
• Conductive: bone conduction normal, air conduction elevated — a mechanical problem in the outer or middle ear (e.g., middle-ear fluid, ossicular malformation). Often medically or surgically treatable and may resolve • Sensorineural: both air and bone conduction equally elevated — damage to the cochlear hair cells or auditory nerve. Permanent; managed with amplification or implantation, not surgery • Mixed: both a conductive and a sensorineural component are present simultaneously
Genetic evaluation and congenital CMV testing (via urine or saliva PCR, ideally within the first 3 weeks of life while still diagnostic) are recommended for every infant with confirmed permanent hearing loss, both to explain etiology and because CMV-related loss can be progressive or fluctuating — changing the monitoring plan.
Because congenital CMV hearing loss can appear normal at birth and progress later, and because roughly a third of childhood hearing loss overall is progressive or late-onset, the audiogram at diagnosis is a snapshot, not a lifetime guarantee — ongoing audiologic monitoring remains essential even after a normal newborn screen.
The Joint Committee on Infant Hearing maintains a list of risk indicators associated with delayed-onset or progressive hearing loss that justify continued audiologic monitoring even after an infant passes the newborn screen, including: NICU stay greater than 5 days, extracorporeal membrane oxygenation (ECMO), exposure to ototoxic medications (aminoglycosides, loop diuretics) or chemotherapy, hyperbilirubinemia requiring exchange transfusion, in utero infections (CMV, herpes, rubella, syphilis, toxoplasmosis), craniofacial anomalies including ear/temporal bone anomalies, family history of permanent childhood hearing loss, and syndromes known to include hearing loss (e.g., Usher, Waardenburg, CHARGE).
These infants are typically recommended for a repeat diagnostic audiologic assessment by 24-30 months regardless of newborn screening result.
The final and most consequential milestone in the 1-3-6 pathway is enrollment in early intervention by 6 months of age — hearing aids, cochlear implant candidacy evaluation, and structured language-development services. Decades of outcome research converge on one message: infants identified and enrolled early enter kindergarten with language skills statistically indistinguishable from hearing peers; those identified late do not catch up.
The auditory cortex and the broader language-processing network undergo their most rapid, experience-dependent wiring in the first two to three years of life, with a particularly steep curve in the first six months. Every month a developing brain lacks access to structured auditory input is a month of "lost" input during the period when the brain is maximally primed to build the neural architecture for spoken language, even though the raw capacity for hearing itself may be restorable at any age with amplification or implantation.
Landmark longitudinal research (notably the Colorado and Australian LOCHI studies) found that children identified and enrolled in intervention before 6 months achieved vocabulary and language scores within the normal range by preschool and school age, while comparable children identified after 6-12 months showed persistent, often widening gaps in expressive and receptive language, regardless of hearing device used.
The magnitude of the early-vs-late intervention effect on language outcomes at school age is comparable to, or larger than, the effect of the degree of hearing loss itself — timing is at least as important as severity.
Intervention is individualized to the audiogram and family communication goals:
• Hearing aids: appropriate for mild-to-severe sensorineural loss; digital behind-the-ear (BTE) aids are custom-fit and re-programmed frequently as the ear canal grows, often within weeks of confirmed diagnosis • Cochlear implants: for bilateral severe-to-profound loss with limited benefit from hearing aids, a surgically implanted electrode array directly stimulates the auditory nerve, bypassing non-functional hair cells; candidacy evaluation should begin as soon as severity is confirmed even though surgery itself typically occurs around 9-12 months • Bone-conduction devices: for conductive or mixed losses, particularly with aural atresia or chronic middle-ear disease • Early intervention / listening-and-spoken-language therapy: regardless of device, weekly developmental and speech-language therapy builds the auditory-verbal or visual-language skills that a device alone cannot provide • American Sign Language and Deaf-community engagement: families who choose a signing-first or bilingual (ASL + spoken language) approach benefit equally from early enrollment — the "critical period" applies to language acquisition broadly, not only spoken language
The Early Hearing Detection and Intervention system defines success as every infant with permanent hearing loss being screened by 1 month, diagnosed by 3 months, and enrolled in intervention by 6 months — the "1-3-6" benchmark. National surveillance shows steady but incomplete progress: screening coverage now exceeds 98%, but only roughly six in ten diagnosed infants nationally are enrolled in intervention by the 6-month mark, with loss to follow-up between screening and diagnosis remaining the single largest point of attrition.
Closing this gap is now understood primarily as a systems and equity challenge rather than a technology challenge — the screening tools, diagnostic tools, and intervention tools all already exist and are effective. What remains is building the care-coordination infrastructure to make sure every family who needs them actually reaches them in time.